KEY POINTS
• miR-125b is epigenetically silenced in B cells.
• Physiological silencing of miR-125b is required for normal B cell development.
ABSTRACT
Deregulation of several microRNAs can influence critical developmental checkpoints during hematopoiesis as well as cell functions, eventually leading to the development of autoimmune disease or cancer. We found that miR-125b is expressed in bone marrow multipotent progenitors and myeloid cells but is shut down in the B cell lineage, and the gene encoding miR-125b lacked transcriptional activation markers in B cells. To understand the biological importance of the physiological silencing of miR-125b expression in B cells, we drove its expression in the B cell lineage and found that dysregulated miR-125b expression impaired egress of immature B cells from the bone marrow to peripheral blood. Such impairment appeared to be mediated primarily by inhibited expression of the sphingosine-1-phosphate receptor 1 (S1PR1). Enforced expression of S1PR1 or CRISPR/Cas9-mediated genome editing of the miR-125b targeting site in the S1PR1 3'UTR rescued the miR125b-mediated defect in B cell egress. In addition to impaired B cell egress, miR-125b dysregulation initially reduced pre-B cell output, but later induced pre-B cell lymphoma/leukemia in mice. Genetic deletion of IRF4
was found in miR-125b induced-B cell cancer but its role in oncogenic miR-125b-induced B cell transformation is still unknown. Here, we further demonstrated an interaction of the effects of miR-125b and IRF4 in cancer induction by showing that miR125b-induced B cell leukemia was greatly accelerated in the IRF4 homozygous mutant mice. Thus, we conclude that physiological silencing of miR-125b is required for normal B cell development and also acts as a mechanism of cancer suppression.
For personal use only. on March 27, 2018. by guest www.bloodjournal.org From INTRODUCTION B cells produce antibodies that react with foreign antigens and can help eliminate pathogenic invaders. Early B cell development in the bone marrow is tightly controlled by multiple transcription factors, including PU.1, E2A, Pax5 and EBF1 1 . Several factors, including sphingosine-1-phosphate receptor 1 (S1PR1), have been
shown to mediate B cell egress from bone marrow [2] [3] [4] [5] .
Mature miR-125b is encoded in two different genomic regions: miR-125b-1 is located on chromosomes 11
and 9 in the human and mouse genomes, respectively; miR-125b-2 located on human chromosome 21 and mouse chromosome 16 6 . Dysregulated miR-125b expression has been found in many neoplastic blood disorders, including B-cell precursor acute lymphoblastic leukemia (BCP-ALL) 6 , suggesting that miR-125b might act as an oncomiR able to transform cells by targeting genes involved in tumorigenesis. Indeed, overexpression of miR-125b alone in mice is sufficient to induce tumors in multiple hematopoietic lineages generating myeloid, T cell and B cell leukemias [7] [8] [9] [10] [11] . Several target genes have been identified and postulated to have a role in the oncogenic properties of overexpressed miR-125b, such as Trp53inp1 and MAP3K11, which facilitate cell survival 8, 12 . A genetic deletion of the gene encoding IRF4 has also been reported in miR-125b dysregulation-induced B cells 11 . In addition to promoting leukemia, several in vitro studies also suggest a role for this microRNA in B cell development and differentiation. For instance, overexpression of miR-125b in primary B cells impairs LPS induction of these cells into plasma cells in vitro 13 . Despite these findings, the role of miR-125b in the early stages of B cell development in vivo and the underlying molecular mechanism of oncomiR miR-125b in B cell tumorigenesis are largely unknown.
In this study, we found miR-125b is epigenetically silenced during the development of normal B cells. To examine the biological importance of the physiological silencing of miR-125b expression in the B cell lineage, we used transgenic (Tg) mice that overexpress miR-125b under the control of the Ig intronic enhancer Eμ. We found that B cell-specific miR-125b expression results in impaired release of immature B cells from the bone marrow into the blood. We identified S1PR1 as a target of miR-125b in B cells and showed that enforced expression of S1PR1 or CRISPR/CAS9-mediated genome editing of the miR-125b binding site within the S1PR1 3'UTR rescues the egress defect resulting from miR-125b dysregulation. In addition to impaired B cell egress, miR-125b dysregulation initially reduces pre-B cell output but later induces pre-B cell lymphoma/leukemia. Genetic deletion of IRF4 was found in miR-125b-induced B cell cancer but its role in oncogenic miR-125b-induced B cell transformation is still unknown. Here, we further demonstrated an interaction of the effects of miR-125b and IRF4 in cancer induction by showing that miR-125b-induced B cell leukemia is greatly accelerated in IRF4 homozygous mutant mice. Thus, we have uncovered a novel role for miR-125b as a negative regulator of early B cell development and conclude that epigenetic silencing of miR125b is required for normal B cell development.
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METHODS

Animals
All mice were maintained in the Caltech Office of Laboratory Animal Resources (OLAR) facility (all protocols were in accordance to the rules and regulations of the Institutional Animal Care and Use Committee of California Institute of Technology).
DNA constructs
For luciferase assays, the microRNA-125b expression cassette was subcloned into the pMG vector. The 3'UTR of S1PR1 containing the miR-125b-binding site was cloned immediately downstream of luciferase in the pMiReport vector as previously described 14 . For S1pr1 rescue experiments, S1PR1 lacking its 3'UTR was cloned into the MSCV-eGFP vector. A gRNA targeting Cas9 to the miR-125b binding site in S1PR1 3'UTR was cloned into a retroviral vector bearing cyan fluorescent protein (CFP).
Cell culture
Cells were cultured in a sterile incubator that was maintained at 37°C and 5% CO 2 . HEK293T cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin.
Labeling of bone marrow sinusoidal and parenchymal B cells
To detect bone marrow sinusoidal and parenchymal B cells, we adapted an in vivo labeling procedure as previously described 4 . Eμ/miR-125b Tg mice and littermate controls were injected intravenously with 1 
Flow cytometry
Respective tissue samples were collected from the appropriate mice as indicated in the text and processed as previously described 14 (detailed in supplemental methods).
Epigenetic Analysis
The epigenetic analysis was described previously 15 . See the supplemental Methods for detailed experimental setup and data analysis.
Statistical analysis
All statistical analysis was done in GraphPad Prism software using an unpaired Student's t-test. Data were reported as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant.
Accession number
All sequencing data are available in the NCBI's Gene Expression Omnibus (GEO) database under the accession number GSE82144.
RESULTS
Epigenetic regulation of miR-125b expression in B cells
To investigate the role of miR-125b in B cells, we first examined its expression in mouse spleen and bone marrow cells as well as various types of immune cells. We found that the expression of miR-125b-5p and 3p (two mature microRNAs originating from opposite arms of the same miR125b-1 pre-miRNA) was much higher in macrophages compared with other immune cells and tissues. In contrast, purified splenic B cells expressed an extremely low level of both miR-125b-5p and 3p ( Figure 1A) . Further analysis of their expression in sorted bone marrow lineage-negative, Sca-1 + , c-Kit + (LSK) cells and B cell subset populations showed reduced expression of these microRNAs throughout B lymphocyte lineage differentiation ( Figure 1B) . To determine how miR-125b expression is regulated, we examined histone modifications in the genome locus of the two genes encoding miR-125b by chromatin immunoprecipitation (ChIP) sequencing 15 . The promoter region of the miR-125b-1-encoding gene displayed a high level of the repressive modification H3K27me3 and lacked activating modifications including H3K14ac, H3K36ac, H3K4me3, H3K79me2 and H4K91ac. We also detected no p300 or RNA polymerase II (PolII) enrichment in the promoter region, consistent with this region's transcriptional silencing ( Figure 1C ). In these resting B cells, the miRNA-125b-2 locus also lacked active modifications and p300/PolII recruitment in its promoter region, although it lacked repressive marks as well. By contrast, miR-15b/16 clusters are actively expressed during lymphopoiesis and required for controlling B cell proliferation 16 . We confirmed that miR-15b/16 clusters displayed a high degree of activating modifications as well as p300 and PolII recruitment in the promoter region of their encoding gene ( Figure 1C ), acting as a control for the effectiveness of our assay. We also examined the active modification H3K4me3 and repressive modification H3K27me3 in miR-125b encoding genes in pro-B cells, pre-B cells and LPS plus IL-4 activated B cells. We found that these B cell subsets displayed similar histone modification patterns to those observed in resting B cells ( Figure S1A ). Thus, these data suggest that miR-125b is epigenetically silenced as hematopoietic cells transition from pluripotency to differentiated B cells.
Dysregulated miR-125b expression reduced number of B cells in the blood and spleen
To understand the biological importance of the physiological down-regulation of miR-125b expression in B cells, we examined the effect of overexpression of miR-125b on B cell development using Eμ/miR-125b-Tg mice. These mice overexpressed miR-125b (200-400 fold higher than the control mice) only in B lineage cells throughout their development ( Figure S2A ). B cells (B220 + ) were quantified in the bone marrow, blood, spleen, and peripheral lymph nodes (PLNs) of wild-type (WT) and Eμ/miR-125b-Tg mice at 8 weeks of age. A decreased frequency and number of B220 + B cells was evident in Eμ/miR-125b-Tg mice in all of these compartments, with the most striking differences evident in the blood and PLNs ( However, the immature B cell population showed significantly more annexin V + staining in Eμ/miR-125b-Tg mice than control mice, indicating an increased incidence of cell death ( Figure 4C and S4A) .
Interaction of chemokine (C-X-C motif) receptor 4 (CXCR4) with its ligand SDF-1 is required for bone marrow retention of developing B cells in the parenchyma [2] [3] [4] 18 . When control mice were treated with AMD3100, a potent CXCR4 antagonist, immature bone marrow B cells (B220 + CD93 + ), CD3 + T lymphocytes and CD11b + myeloid cells were released into peripheral blood ( Figure 4D ). The release of immature B cells
For personal use only. on March 27, 2018. by guest www.bloodjournal.org From into the blood was significantly lower in Eμ/miR-125b-Tg mice than in control mice after AMD3100 treatment, suggesting that miR-125b still inhibited B cell release from the bone marrow even when CXCR4 signaling was attenuated. Taken together, these findings indicate that dysregulated miR-125b expression causes the retention of immature B cells inside bone marrow sinusoids, leading to an increase in apoptosis.
Sphingosine-1-phosphate receptor 1 (S1PR1) is a direct target of miR-125b
We next sought to better understand the underlying molecular mechanism for the defect in B cell egress in Eμ/miR-125b-Tg mice. In a computational online search with TargetScan/MicroRNA, we identified a potential target of miR-125b, S1PR1, which is a key regulator of the process of immature B cell release from the bone marrow [2] [3] [4] 19 ( Figure 5A) . RNA was extracted from bone marrow B220 + B cells of Eμ/miR-125b-Tg and control mice and then subjected to quantitative polymerase chain reaction (qPCR) to examine the effect of miR125b on S1PR1 expression. We found significantly reduced S1PR1 mRNA expression levels in dysregulated miR-125b-expressing B cells compared with controls ( Figure 5B ). In contrast, the expression of S1PR2 and S1PR3, two other members in the S1P receptor family that lack a miR-125b binding site in their 3' UTR, remained unchanged. We next determined whether S1PR1 might represent a direct target of miR-125b by performing luciferase assays as previously described 20 . A luciferase reporter, in which the S1PR1 3'UTR was placed immediately downstream of luciferase, was transfected into HEK293 cells with either the miR-125b or a control vector. Overexpression of miR-125b significantly reduced luciferase activity, indicating the S1PR1 3'UTR is a direct target ( Figure 5C ). We next quantified S1pr1 protein expression in B cells from Eμ/miR125b-Tg and control mice. Consistent with S1PR1 being a target of miR-125b, we found protein expression was significantly downregulated in B cells with dysregulated miR-125b expression (Figure 5D and S5A) . In addition to CXCR4 signaling, the exit of immature B cell from bone marrow also relies on egress-promoting activity of S1P and S1PR1, which were thought to provide release signals for immature B cells 2, 5 . We next investigated if S1PR1 is the key target of miR-125b responsible for regulating B cell egress. To do this, we attempted to rescue the defect in B cell exit observed in Eμ/miR-125b-Tg mice by expressing S1PR1 that lacked the miR-125b-binding site. Hematopoietic stem/progenitor cells (HSPCs) from WT and Eμ/miR-125b-Tg were transduced with either a control vector (MSCV) or a S1PR1 expressing vector (MSCV-S1PR1) lacking the S1PR1 3'UTR, and were then subsequently used to reconstitute lethally irradiated WT mice ( Figure S5B ). We first validated the expression of S1PR1 in the respective samples by RT-qPCR ( Figure S5C) . Analysis of the peripheral blood of mice at 7 weeks after reconstitution revealed that expression of S1PR1 partially rescues the loss of peripheral B cells observed with dysregulated miR-125b expression ( Figure 5E ).
We further attempted to genetically disrupt the miR-125b targeting site in 3'UTR of S1PR1 using the CRISPR/Cas9 system to see if it would rescue such a defect. We designed a gRNA to target Cas9 to miR-125b binding site in S1PR1 3'UTR and this gRNA was cloned into a retroviral vector bearing cyan fluorescent protein (CFP) (Figure 5F and S5D) . To test the efficiency of the gRNA, we infected HSPCs with retroviruses to deliver the gRNA into cells and performed a surveyor assay (a mismatch cleavage assay) to measure the insertions/deletions (indels) at the S1PR1 3'UTR locus 21 . Efficient editing in the UTR locus was observed ( Figure 5G ). Sequencing confirmed that this gRNA efficiently induced indel mutations ( Figure S5E) . To track
For personal use only. on March 27, 2018. by guest www.bloodjournal.org From the reconstitution with bone marrow-derived elements, we next reconstituted recipient C57BL/6 mice (CD45.1) with HSPCs from Cas9 Tg (CD45.2) or Eμ/miR-125b-Cas9 Tg (CD45.2) mice, which were transduced with a vector expressing a control gRNA, or a vector expressing S1PR1 3'UTR targeting gRNA ( Figure S5F ). Flow cytometric analysis was performed to examine the B cell egress 7 weeks after reconstitution of recipient mice with sorted CFP + bone marrow cells. We found a significant increase in total B cells (B220 + ) in the mice reconstituted with HSPCs expressing S1PR1 3'UTR-targeting gRNA compared with the mice reconstituted with
HSPCs expressing control gRNA ( Figure 5H ). These results demonstrate a specificity of miR-125b targeting for S1PR1 in B cell egress.
IRF4 is a suppressor of miR-125b induced B cell leukemia
Along with impaired output of pre-B cell and impaired immature B cell egress, transgenic miR-125b expression causes lymphoblastic leukemia in mice 7, 8, 11 . Our lab has previously found that miR-125b dysregulation-induced BCP-ALL displays a genetic deletion of the gene encoding IRF4 11 . However, whether IRF4 plays a role in 
DISCUSSION
Dysregulated miR-125b expression has been found in myeloid and B-cell leukemia. In this study, we have provided evidence for a deleterious role of miR-125b expression in the B cell lineage and uncovered the mechanism underlying tumorigenesis and impaired immature B cell egress from bone marrow. We showed that the expression of miR-125b is epigenetically silenced during the development of normal B cells. Unregulated miR-125b expression leads to inefficient appearance of immature B cells in peripheral blood and also induces pre-B cell leukemia. The mechanism by which miR-125b is deleterious to B cell production clearly involves at least its effect on S1PR1, a previously unappreciated target for miR-125b affecting B cell egress. In addition, miR-125b dysregulation leads to a pro-oncogenic state that becomes evident when an IRF4 deletion occurs, showing that the pro-oncogenic state is controlled by IRF4. Thus, our previous observation that the tumors in 3 . We found that AMD3100, a specific inhibitor of CXCR4, stimulated the release of B cell precursors from bone marrow in control mice but not in Eμ/miR-125b Tg mice, excluding the possibility that inefficient B cell egress in Tg mice is due to disruption of CXCR4-mediated retention.
Searching for a mechanism by which miR-125b exerts its effect on the B cell egress, we found that the direct target of miR-125b, S1PR1, is a key regulator of the process of immature B cell release from the bone marrow. We found that enforced expression of S1PR1 in donor cells from Eμ/miR-125b Tg mice almost restored normal B cell egress, suggesting that S1PR1 is a critical target of miR-125b in regulating immature B cell release in Eμ/miR-125b Tg mice. The CRISPR/Cas9 system can be used to edit mammalian germline sequences and cell lines 23, 24 . To exclude the possibility that S1PR1 replenishes the immature B cell pool in peripheral blood through an indirect mechanism unrelated to the function of miR-125b in B cells, we used CRISPR/Cas9-mediated genome engineering technology to edit out the miR-125b binding site in the S1PR1 3'UTR, preventing targeting by miR-125b. Notably, we were able to partially rescue the defect of B cell egress upon target-editing of the miR-125b-binding site in the cells from Eμ/miR-125b Tg mice. Our data suggests that S1PR1 is one of the critical targets of miR-125b in regulating immature B cell release from bone marrow in Eμ/miR-125b Tg mice. Some other targets of miR-125b might also contribute to the reduced total B cell numbers in the periphery of the Tg mice. BCL2, which can protect against apoptosis and is required for cell cycle entry and proliferation, was previously identified as a target for miR-125b 25 . We found its expression was downregulated in B cells from Eμ/miR-125b Tg mice ( Figure S5G ). In addition, the expression of E2F2, a potential miR-125b targeting gene that is critical for cell cycle transition 26 , was also reduced in the B cells from Eμ/miR-125b Tg mice. Downregulation of these genes might have an important role in B cell survival and proliferation in the periphery of Eμ/miR-125b Tg mice, especially when peripheral B cells encounter antigens.
Thus, downregulation of S1PR1, BCL2 and E2F2 in B cells with dysregulated miR-125b expression could all contribute to the peripheral B cell deficiency in Eμ/miR-125b Tg mice.
Overexpression of miR-125b in mice initially reduced pre-B cell output, but later induced pre-B cell lymphoma/leukemia, with acquisition of a genetic deletion of the tumor suppressor IRF4 gene 11, 14 , suggesting a potential role of IRF4 in miR-125b-induced B-cell cancer. MiR-125 has been shown to target IRF4 13 .
However, we found that miR-125b has no significant impact on IRF4 expression in resting B cells (data not shown). Notably, we found that miR-125b-induced acute pre-B cell leukemia was greatly accelerated in the IRF4 homozygous mutant mice and enforced expression of IRF4 in donor cells from Eμ/miR-125b Tg mice, which are prone to develop pre-B cell cancer, had a protective effect on cancer development. This further suggests that genetic depletion of IRF4 makes the miR-125b-overexpressing B cells more susceptible to becoming cancerous.
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